Advancing Therapy in Basal Insulin-Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline HbA1c, Insulin Dose, and BMI

被引：0
|
作者：
Home, Philip
McCrimmon, Rory J.
Rosenstock, Julio
Bluher, Matthias
Pegelow, Katrin
Melas-Melt, Lydie
Djaballah, Khier
Giorgino, Francesco
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-845-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
845-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials
    Giugliano, D.
    Maiorino, M.
    Bellastella, G.
    Chiodini, P.
    Esposito, K.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (05) : 602 - 612
  • [22] Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA1c in insulin-treated diabetes (MITRE Study)
    Cooke, D.
    Hurel, S. J.
    Casbard, A.
    Steed, L.
    Walker, S.
    Meredith, S.
    Nunn, A. J.
    Manca, A.
    Sculpher, M.
    Barnard, M.
    Kerr, D.
    Weaver, J. U.
    Ahlquist, J.
    Newman, S. P.
    DIABETIC MEDICINE, 2009, 26 (05) : 540 - 547
  • [23] Basal insulin peglispro is superior to insulin glargine in reducing HbA1c in insulin-naive patients with type 2 diabetes treated with oral antihyperglycaemic drugs: IMAGINE 2
    Davies, M. J.
    Russell-Jones, D.
    Selam, J. -L.
    Bailey, T. S.
    Kerenyi, Z.
    Luo, J.
    Bue-Valleskey, J.
    Ivanyi, T.
    Hartman, M. L.
    Jacobson, J. G.
    Jacober, S. J.
    DIABETOLOGIA, 2015, 58 : S19 - S20
  • [24] Advancing therapy in basal insulin users with type 2 diabetes: better clinical outcomes with iGlarLixi vs premix BIAsp 30 in the SoliMix trial
    Trescoli, C.
    Rosenstock, J.
    Emral, R.
    Sauque-Reyna, L.
    Mohan, V.
    Al Sifri, S.
    Lalic, N.
    Alvarez, A.
    Picard, P.
    Demil, N.
    Bonnemaire, M.
    McCrimmon, R. J.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 111 - 111
  • [25] Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes
    Monnier, L
    Colette, C
    Thuan, JF
    Lapinski, H
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (04) : 231 - 235
  • [26] Effect of orlistat on insulin resistance in patients with type 2 diabetes with baseline HbA1c levels ≥8%
    Rissanen, A
    Hollander, P
    DIABETES, 2002, 51 : A413 - A413
  • [27] Efficacy and Safety of Fast-Acting Insulin Aspart According to Baseline HbA1c in Adults with Type 2 Diabetes Treated with a Basal-Bolus Regimen
    Franek, Edward
    Ekelund, Magnus
    Thorisdottir, Olof
    Jang, Hak Chul
    Lalic, Katarina
    Rathor, Naveen
    Rose, Ludger
    Gonzalez, Alfonso Soto
    Silver, Robert J.
    Lane, Wendy
    DIABETES, 2020, 69
  • [28] Basal insulin and oral antidiabetic therapy (BOT)+ a single dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with type 2 diabetes
    Lankisch, Mark
    Ferlinz, Kaus
    Scherbaum, Werner A.
    DIABETES, 2007, 56 : A51 - A52
  • [29] Basal insulin and oral antidiabetic therapy (BOT)+ a single dose of insulin glulisine (BOT+) reduces HbA1c and blood glucose values in patients with type 2 diabetes
    Lankisch, M.
    FerlinZ, K.
    Scherbaum, W. A.
    DIABETOLOGIA, 2007, 50 : S404 - S405
  • [30] THE IMPACT OF BASELINE HBA1C AND HBA1C TRAJECTORIES ON TIME TO THERAPY ESCALATION IN TYPE 2 DIABETES MELLITUS
    McEwan, P.
    Foos, V
    Larnotte, M.
    VALUE IN HEALTH, 2015, 18 (07) : A698 - A698
12345